Q4 2025 Protalix Biotherapeutics Inc Earnings Call Transcript

Mar 18, 2026 / 12:00 PM GMT

Release Date Price: $2.21 (-20.79%)

Transcript 10-K8-K

Key Points

Positve

The European Commission approved a new dosing regimen for EFrio, enhancing treatment options for Fabry disease patients in the EU.
Protalix BioTherapeutics Inc (PLX) received a EUR25 million milestone payment following the EU approval, boosting their financial position.
Projected cash balance of approximately $50 million by early April 2026, providing strong financial flexibility.
Expected revenue growth of over 50% in 2026, driven by increased patient numbers and milestone payments.
Advancement of PRX 115 in the pipeline, with phase 2 trials underway, indicating strong momentum in R&D.

Negative

Net loss of $6.6 million recorded for 2025, compared to a net income of $2.9 million in 2024, reflecting increased R&D investments.
R&D expenses increased by 51% year over year, indicating higher costs associated with advancing the clinical pipeline.
Cost of goods sold increased to $27 million, driven by higher sales volume and manufacturing issues at Pfizer.
Revenue from licensed and R&D services remains minimal, indicating limited diversification in revenue streams.
Uncertainty around the timing of US approval for the new dosing regimen, which could impact future sales growth.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

PLX.A - Protalix Biotherapeutics Inc
Q4 2025 Protalix Biotherapeutics Inc Earnings Call
Mar 18, 2026 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning, ladies and gentlemen, and welcome to Protalix Biotherapeutics Full Year 2025 financial results and business update conference call. As a reminder, this call is being recorded. I will now turn the conference over to Mike Moyer, managing director of Life Site Advisors and investor relations representative for Protalix.

Thank you. You may begin.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator, and welcome to the Protalix Biotherapeutics full year 2025 financial results and business update conference call. With me today are Door

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.